BSE Limited Registered Office: Floor 25, P. Towers, Dalal Street, Mumbai 400 001 India T: +91 22 2272 1234 / 33 F: +91 22 2272 1003 www.bseindia.com CIN NO:U67120MH2005PLC155188



DCS/AMAL/SJ/24(f)/26/2014-15

May 2, 2014

The Company Secretary
Glenmark Pharmaceuticals Ltd
Glenmark House, HDO –Corporate Building,
Wing A, B D Sawant Marg,
Chakala, Off Western Express Highway,
Andheri (E),
Mumbai- 400 099

Dear Sir / Madam,

Sub: Observation letter regarding the Scheme of Amalgamation between Glenmark Generics Ltd (GGL) and Glenmark Access Ltd(GAL) with Glenmark Pharmaceuticals Ltd(GPL).

We are in receipt of draft Scheme of Amalgamation involving merger of the company with Glenmark Generics Ltd (GGL) and Glenmark Access Ltd (GAL).

The Exchange has noted the confirmation given by the Company stating that the scheme does not in any way violate or override or circumscribe the provisions of the SEBI Act, 1992, the Securities Contracts (Regulation) Act, 1956, the Depositories Act, 1996, the Companies Act, 1956, the rules, regulations and guidelines made under these Acts, and the provisions of the Listing Agreement or the requirements of BSE Limited (BSE).

As required under SEBI Circular No.CIR/CFD/DIL/5/2013 dated February 4, 2013 & SEBI Circular No.CIR/CFD/DIL/8/2013 dated May 21, 2013; SEBI has vide its letter dated April 30, 2014 given the following comment(s) on the draft scheme of arrangement:

- > The company shall duly comply with various provisions of the Circulars.
- > Listed Company shall ensure that the additional document submitted by the company with respect to pre-scheme and post-scheme shareholding is displayed from the date of receipt of this letter on the website of the listed company along with various documents submitted pursuant to the circulars.

Accordingly, we hereby convey Exchange's 'No-objection' with limited reference to those matters having bearing on listing/ delisting/ continuous listing requirements within the provisions of the Listing Agreement, so as to enable you to file the scheme with the Hon'ble High Court.

Further, you are also advised to bring the contents of this letter to the notice of your shareholders, all relevant authorities as deemed fit, and also mention the same in your application for approval of the scheme of arrangement submitted to the Hon'ble High Court.

The Exchange reserves its right to withdraw its No-objection/approval at any stage if the information submitted to the Exchange is found to be incomplete / incorrect / misleading / false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Listing Agreement, Guidelines/Regulations issued by statutory authorities.

Yours faithfully,

Bhuvana Sriram Deputy Manager Pooja Sanghvi Asst. Manager